3-May-2024
No headlines found.
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Mon, 8-Apr 4:01 PM ET)
Business Wire (Thu, 14-Mar 4:01 PM ET)
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Business Wire (Wed, 28-Feb 4:01 PM ET)
PRNewswire (Mon, 26-Feb 6:10 PM ET)
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Kezar Life Sciences trades on the NASDAQ stock market under the symbol KZR.
As of May 3, 2024, KZR stock price was flat at $0.86 with 184,426 million shares trading.
KZR has a beta of 2.90, meaning it tends to be more sensitive to market movements. KZR has a correlation of 0.18 to the broad based SPY ETF.
KZR has a market cap of $62.42 million. This is considered a Micro Cap stock.
In the last 3 years, KZR stock traded as high as $18.55 and as low as $.67.
The top ETF exchange traded funds that KZR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
KZR has underperformed the market in the last year with a return of -67.1%, while the SPY ETF gained +27.0%. In the last 3 month period, KZR fell short of the market, returning -9.3%, while SPY returned +3.7%. However, in the most recent 2 weeks KZR has outperformed the stock market by returning +8.5%, while SPY returned +3.3%.
KZR support price is $.82 and resistance is $.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZR stock will trade within this expected range on the day.